AXL and error-prone DNA replication confer drug resistance and offer strategies to treat EGFR-mutant lung cancer A Noronha, N Belugali Nataraj, JS Lee, B Zhitomirsky, Y Oren, S Oster, ... Cancer discovery 12 (11), 2666-2683, 2022 | 58 | 2022 |
Green Synthesis of Silver Nanoparticles Using the Leaf Extract of the Medicinal Plant, Uvaria narum and Its Antibacterial, Antiangiogenic, Anticancer and Catalytic … AP Ajaykumar, A Mathew, AP Chandni, SR Varma, KN Jayaraj, O Sabira, ... Antibiotics 12 (3), 564, 2023 | 29 | 2023 |
Increased Plasma Nitrite and von Willebrand Factor Indicates Early Diagnosis of Vascular Diseases in Chemotherapy Treated Cancer Patients S Giri, JC Bose, A Chandrasekar, BK Tiwary, P Gajalakshmi, S Chatterjee Cardiovascular toxicology, 1-12, 2018 | 13 | 2018 |
Repurposing of thalidomide and its derivatives for the treatment of SARS‐coV‐2 infections: Hints on molecular action L Sundaresan, S Giri, H Singh, S Chatterjee British Journal of Clinical Pharmacology 87 (10), 3835-3850, 2021 | 12 | 2021 |
Host-Dependent Phenotypic Resistance to EGFR Tyrosine Kinase InhibitorsHost-Dependent Reversibility of TKI Resistance Y Haga, I Marrocco, A Noronha, ML Uribe, NB Nataraj, A Sekar, ... Cancer research 81 (14), 3862-3875, 2021 | 5 | 2021 |
Inhibitors of Nitric Oxide Synthase: What’s up and What’s Next? L Sundaresan, S Giri, S Chatterjee Current Enzyme Inhibition 12 (1), 81-107, 2016 | 5 | 2016 |
A proteome-wide systems toxicological approach deciphers the interaction network of chemotherapeutic drugs in the cardiovascular milieu S Giri, J Manivannan, B Srinivasan, L Sundaresan, P Gajalakshmi, ... RSC Advances 8 (36), 20211-20221, 2018 | 4 | 2018 |
Breast cancer drugs perturb fundamental vascular functions of endothelial cells by attenuating protein S‐nitrosylation S Giri, YT Katakia, S Chatterjee, P Gajalakshmi Clinical and Experimental Pharmacology and Physiology, 2019 | 2 | 2019 |